Biotechnology company Chimerix Inc. granted SymBio Pharmaceuticals Limited exclusive worldwide rights to its drug brincidofovir in all human indications except smallpox.

Chimerix will receive an upfront cash payment of $5 million on or before Oct. 22, and is eligible to receive $180 million in milestone payments as well as low double-digit royalties on sales of brincidofovir. The company announced the deal in a Securities and Exchange Commission filing Thursday afternoon.

Either company may terminate the license agreement upon a material breach or events involving the bankruptcy or insolvency of either party, according to the filing. SymBio, a Tokyo-based pharmaceuticals company, may terminate the license agreement without cause on a country-to-country basis with 90 days prior written notice.

Brincidofovir is an experimental antiviral drug being developed to treat smallpox and a variety of infections. The drug for is currently in Phase 3 of clinical trials for its treatment of smallpox.

Chimerix stock was trading at $1.96 per share on Friday morning, up 2 cents.